Medical news in brief: Weekly insulin ȷab approved, doctors “bullied and harassed” at work, UK bans weight loss pill ads, and other stories
AI Summary
The UK regulator approved Eli Lilly’s once-weekly insulin efsitora alfa, marketed as Onswik, for adults with type 2 diabetes. A separate NHS England report described staff reluctance to raise concerns amid reports of bullying and harassment; the article also notes a UK ban on weight-loss pill advertising.
Type 2 diabetesWeekly insulin jab is approved by MHRAThe UK Medicines and Healthcare Products Regulatory Agency approved the weekly insulin injection efsitora alfa, also known as Onswik and made by Eli Lilly, for adults with type 2 diabetes. The National Institute for Health and Care Excellence recommended the treatment in August, citing clinical trial evidence showing that the drug was as effective as long acting insulins already widely used to treat type 2 diabetes. Unlike current options, Onswik needs to be injected only once a week.Staff wellbeingNHS England staff are reluctant to raise concernsNHS England is a “challenging” environment to work in and staff are unwilling to raise concerns, a report found. The internal Freedom to Speak Up (FTSU) report said that staff who raised concerns faced bullying, harassment, and psychological abuse from seniors.1 In 2025-26 NHS England staff raised 235 FTSU cases, after 319 cases in 2024-25. Issues included...